Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for Supinoxin TM (RX-5902)

Further expands IP covering Supinoxin, following the Company’s receipt of composition of matter patent

ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that it has been issued United States Patent, No. 8,598,173, which covers a method for treating solid cancer tumors including ovarian, breast, prostate, liver, lung, kidney, colon, pancreatic and stomach for its clinical development candidate Supinoxin^TM (RX-5902). Rexahn had previously received a composition of matter patent from the United Stated Patent and Trademark Office covering the structure of Supinoxin.

“We are progressing on schedule with our Phase I dose-escalation clinical trial for Supinoxin in cancer patients with solid cancer tumors. Having initiated patient enrollment in August, we expect data in the first half of 2014, which will help inform the study design for future Phase II trials on Supinoxin,” stated Rexahn CEO Peter D. Suzdak, Ph.D.

“We are committed to developing cancer treatments that specifically target cancer cells, excluding healthy tissue, so that cancer can be treated with increased efficacy and reduced toxicity. Strengthening our IP portfolio as we advance in our clinical trials adds critical value to our company,” added Dr. Suzdak.

In-vitro studies have shown that Supinoxin reduces the spread of 18 different human cancer cells lines. Supinoxin has also shown that it can eliminate cancer cells which were resistant to other widely used cancer drugs including docetaxel, cisplatin and gemcitabine. Supinoxin is an orally available new chemical entity exhibiting potent antitumor properties in several types of tumors and has also show strong anti-proliferative activity against known anti-cancer drug-resistant cancer cells, and a synergistic effect with known anti-cancer drugs as well.

About Supinoxin^TM (RX-5902)

Supinoxin is an orally administered, first-in-class, small molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68). P-p68, which is selectively expressed in cancer cells but absent in normal tissue, increases the activity of multiple cancer related genes including cyclin D1, c-jun and c-myc, and plays a role in tumor progression and metastasis. Over-expression of P-p68 has been observed in solid tumors such as melanoma, colon, ovarian and lung.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin^TM (RX-5902), and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. For more information, please visit www.rexahn.com.

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn’s plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the timing and success of clinical testing; the timing of the conduct of clinical testing; the timing of the receipt and disclosure of clinical data and Rexahn’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

The Trout Group LLC
Tricia Truehart, 646-378-2953
[email protected]

Source: Rexahn Pharmaceuticals, Inc.

Released December 11, 2013